Status:
WITHDRAWN
Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure
Lead Sponsor:
University of Pecs
Conditions:
SARS-CoV-2
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Severe sepsis and septic shock are some of the leading causes of mortality in intensive care unit (ICU) admitted COVID-19 patients. The main cause of early mortality is the uncontrolled release of inf...
Detailed Description
In the early phase of sepsis, the activation of innate immunity plays a significant role. Immune cells enhance the production of pro-inflammatory mediators. These pro-inflammatory mediators are respon...
Eligibility Criteria
Inclusion
- Age \>18 years
- confirmed COVID-19 infection
- ICU admission
- Mechanical ventilation due to COVID-19 pulmonary complications
- Moderate to severe acute respiratory distress syndrome (ARDS)
- CytoSorb therapy indicated by the attending medical team preferably within the first 24 hours, but no later than 48 hours after intubation
- Informed consent for data collection
Exclusion
- Unlikely survival for 24 hours according to the attending physician
- Acute onset of hemato-oncological illness
- Patient already on ECMO
- Immunosuppression: on chronic systemic steroid therapy (\>10 mg prednisolon/day); immunosuppressive agents (i.e.: methotrexate, azathioprine, cyclosporin, tacrolimus, cyclophosphamide)
- Patients with transplanted vital organs
- Thrombocytopenia (\<20,000/uL)
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04422626
Start Date
February 1 2022
End Date
December 1 2022
Last Update
April 20 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.